Research

Hormonal

GLP-1 receptor agonist consumption in Brazil is driven by socioeconomic capacity and access rather than epidemiological need, as evidenced by a significant positive correlation with GDP per capita and no correlation with obesity prevalence.

In Brazil, access to GLP-1 drugs like semaglutide is currently determined by your state's economic wealth rather than your obesity rates. Public health policy has excluded these drugs from free coverage, creating a market where only those with higher income can afford them, regardless of medical need.

ModerateQualifiesMEDIUM confidence
GLP-1 RA consumption was significantly associated with state-level economic capacity (Spearman ρ = 0.50; p = 0.008)... no significant correlation was observed between per capita GLP-1 RA consumption and obesity prevalence across Brazilian states (Spearman's ρ = −0.16; p = 0.415)
Renato Lopes Hurtado et al. · Diabetes Obesity and Metabolism · 2026

Why this rating

Ecological correlation study using administrative data; strong signal but prone to confounding and ecological fallacy.

Source

<scp>GLP</scp> ‐1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation

Renato Lopes Hurtado et al. · Diabetes Obesity and Metabolism · 2026

DOI 10.1111/dom.70609

cross_sectional
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →